SEC 13F Intelligence

Managers / Q4 2020 · view latest →

HARBOURVEST PARTNERS LLC

CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707

Reported Value
$256M
Q4 2020
Positions
26
Filings on Record
32
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Harbourvest Partners LLC reported $256M in U.S.-listed holdings across 26 positions for Q4 2020.

The portfolio is heavily concentrated: SWIUSD alone accounts for 43.5% of reported value.

Compared with Q3 2020, the fund opened 6 new positions and exited 15.

Portfolio Metrics

Turnover
+27.3%
vs prior filed quarter
Top-10 Concentration
+95.1%
share of reported value
Largest Position
+43.5%
Solarwinds
New / Exited
6 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $211MQ4 ’18Q1 ’19: $283MQ2 ’19: $262MQ3 ’19: $240MQ4 ’19: $243MQ4 ’19Q1 ’20: $207MQ2 ’20: $232MQ3 ’20: $270MQ4 ’20: $256MQ4 ’20Q1 ’21: $746MQ2 ’21: $1.0BQ3 ’21: $1.1BQ4 ’21: $782MQ4 ’21Q1 ’22: $490MQ2 ’22: $305MQ3 ’22: $306MQ4 ’22: $299MQ4 ’22Q1 ’23: $297MQ2 ’23: $352MQ3 ’23: $295MQ4 ’23: $299MQ4 ’23Q1 ’24: $219MQ2 ’24: $188MQ3 ’24: $192MQ4 ’24: $203MQ4 ’24Q1 ’25: $154MQ2 ’25: $91MQ3 ’25: $205MQ4 ’25: $174MQ4 ’25Q1 ’26: $101Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 64.4%Other: 34.5%ADR: 1.0%
  • Common Stock · 64.4% · $165M
  • Other · 34.5% · $88M
  • ADR · 1.0% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Sigilon Therapeutics, Inc.NEW+740.7K740.7K+$36M$36M
WORKSlack Technologies, Inc.NEW+61.0K61.0K+$3M$3M
MCRB1EURSeres Therapeutics, Inc.NEW+83.9K83.9K+$2M$2M
ADVMCHFAdverum Biotechnologies, Inc.NEW+134.2K134.2K+$1M$1M
YumanityNEW+22.0K22.0K+$375,000$375,000
Rapt Therapeutics, Inc.NEW+12.4K12.4K+$244,000$244,000
1Life Healthcare, Inc.SOLD OUT−351.5K0−$10M$0
PluralSight, Inc.SOLD OUT−176.8K0−$3M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SWIUSDSolarwinds Corp.history →Common43.46%$111M7.44M
2Evelo Biosciences, Inc.Common14.47%$37M3.06M
3Sigilon Therapeutics, Inc.Common13.90%$36M740.7K
4KLDOKaleido BioSciences, Inc.history →Common6.52%$17M1.83M
5Axcella Health, Inc.Common5.69%$15M2.81M
6TDOCTelaDoc Health, Inc.history →Common3.98%$10M50.9K
7RUBYUSDRubius Therapeutics, Inc.history →Common2.93%$7M986.9K
8LCEURLendingClub Corp.history →Common2.12%$5M513.4K
9LOVUSDSpark Networks SEhistory →Sponsored ADR1.04%$3M502.6K
10WORKSlack Technologies, Inc.history →Common CL A1.01%$3M61.0K
11ZUOUSDZuora, Inc.Common0.89%$2M163.9K
12MCRB1EURSeres Therapeutics, Inc.Common0.80%$2M83.9K
13YEXTYext, Inc.Common0.71%$2M115.1K
14ADVMCHFAdverum Biotechnologies, Inc.Common0.57%$1M134.2K
15PGNYProgyny, Inc.Common0.49%$1M29.7K
16ARAntero Resources LLCCommon0.28%$719,000131.9K
17CTMXCytomx Therapeutics, Inc.Common0.20%$519,00079.2K
18Trevena, Inc.Common0.20%$500,000233.8K
19CSLT1EURCastlight Health, Inc.Common CLB0.18%$454,000349.1K
20YumanityCommon0.15%$375,00022.0K
21XGNExagen, Inc.Common0.13%$343,00026.0K
22EPZMEUREpizyme, Inc.Common0.10%$268,00024.7K
23Rapt Therapeutics, Inc.Common0.10%$244,00012.4K
24NXTCEURNextCure, Inc.Common0.04%$109,00010.0K
25Ramaco Resources, Inc.Common0.02%$43,00015.0K
26HNRGHallador Energy Resources, Inc.Common0.01%$21,00014.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$101M5May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$174M7Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$205M9Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$91M15Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$154M16May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$203M22Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$192M34Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$188M40Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$219M48May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$299M53Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$295M58Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$352M60Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$297M63May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$299M65Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$306M67Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$305M62Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$490M66May 26, 2022RESTATEMENTchanges · EDGAR ↗
Q4 2021$782M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.1B56Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.0B51Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$746M44May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$256M26Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$270M36Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$232M28Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$207M36May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$243M35Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$240M33Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$262M32Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$283M33May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$211M32Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.